Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.87 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.87 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.63 |
| ▸ | DUS2 | Q9NX74 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17538540 | 1.00 | EGFR (0.87) | EGFRERBB2KDRERBB3DUS2 | |
| SCHEMBL19027162 | 0.93 | EGFR (0.88) | EGFRERBB2KDRERBB3DUS2 | |
| SCHEMBL17538532 | 0.93 | EGFR (1.00) | EGFRERBB2KDRERBB3DUS2 | |
| SCHEMBL17538534 | 0.93 | EGFR (1.00) | EGFRERBB2KDRERBB3DUS2 | |
| SCHEMBL21761366 | 0.92 | EGFR (0.84) | EGFRERBB2 | |
| SCHEMBL17538499 | 0.92 | EGFR (0.85) | EGFRERBB2KDRERBB3DUS2 | |
| SCHEMBL17538531 | 0.91 | EGFR (0.84) | EGFRERBB2KDRERBB3DUS2 | |
| SCHEMBL17538530 | 0.91 | EGFR (0.84) | EGFRERBB2KDRERBB3DUS2 | |
| SCHEMBL17538496 | 0.91 | EGFR (0.86) | EGFRERBB2KDRERBB3DUS2 | |
| SCHEMBL17538538 | 0.89 | EGFR (1.00) | EGFRERBB2ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196365-B2 | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | ARROMAX PHARMATECH CO., LTD. (CN) | 2019-02-05 | — | — | US | disclosed |
| US-10196365-B2 | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | ARROMAX PHARMATECH CO., LTD. (CN) | 2019-02-05 | — | — | US | disclosed |
| US-20170247339-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247339-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| EP-3181553-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Arromax Pharmatech Co., Ltd. (CN) | 2017-06-21 | — | — | EP | disclosed |
| EP-3181553-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Arromax Pharmatech Co., Ltd. (CN) | 2017-06-21 | — | — | EP | disclosed |
| WO-2016023217-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 安润医药科技（苏州）有限公司 | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247339-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | WEE1, WEE2, EGFR | EGFR 3/4885ERBB2 18/4885KDR 133/4885 |
| US-10196365-B2 | Quinazoline derivative, preparation method therefor, and pharmaceutical composition and application thereof | WEE1, WEE2, EGFR | EGFR 3/4885ERBB2 18/4885KDR 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.